Costo efficacia di peginterferone α-2a + ribavirina verso peginterferone α-2b + ribavirina nel trattamento dell'epatite cronica di tipo C in pazienti non pretrattati

Translated title of the contribution: Cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin as initial therapy for patients with Chronic Hepatitis C

Roberto Ravasio, P. Sacchi, L. Maiocchi, S. Patruno, R. Bruno, G. Filice

Research output: Contribution to journalArticle

Abstract

Introduction: The objective of this study was to evaluate the cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin as initial therapy for patients with Chronic Hepatitis C (CHC). Methods: We used a pre-existent Markov model of disease progression in which two cohorts of patients received peginterferon α-2a plus ribavirin or peginterferon α-2b plus ribavirin for 48 weeks and were followed for their expected lifetimes. The reference patient was a 45-year-old male with CHC without cirrhosis. The sustained virological responses (SVR) with peginterferon α-2a plus ribavirin and peginterferon α-2b plus ribavirin, were taken from two different publications. Utilities and costs for each health state were based on literature estimates and on Italian treatment patterns. Costs in 2005 euros and benefits were discounted at 3%. Sensitivity analyses on key clinical and economic parameters were performed. The analysis was conducted from the perspective of the Italian National Health Service. Results: For the two cohorts expected life-years with peginterferon α-2a plus ribavirin versus peginterferon α-2a plus ribavirin were respectively 30.85 and 30.15 years. Quality-adjusted life years for peginterferon α-2a plus ribavirina were 17.69, and for peginterferon α-2b plus ribavirin were 17.08. The expected cost was €18,272 with peginterferon α-2a plus ribavirin and €18,549 with peginterferon α-2b plus ribavirin. Conclusion: This economic evaluation suggests that peginterferon α-2a plus ribavirin is a dominant strategy versus peginterferon α-2b plus ribavirin for treatment of adults with CHC, under some assumptions regarding treatment effectiveness and model structure.

Original languageItalian
Pages (from-to)207-218
Number of pages12
JournalPharmacoEconomics - Italian Research Articles
Volume7
Issue number3
Publication statusPublished - 2005

Fingerprint

Ribavirin
Chronic Hepatitis C
Cost-Benefit Analysis
Therapeutics
Costs and Cost Analysis
Quality-Adjusted Life Years
National Health Programs
Health Care Costs
Disease Progression
Publications
Fibrosis

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology

Cite this

@article{e700e8a104124e6a997ee8b7862aefc3,
title = "Costo efficacia di peginterferone α-2a + ribavirina verso peginterferone α-2b + ribavirina nel trattamento dell'epatite cronica di tipo C in pazienti non pretrattati",
abstract = "Introduction: The objective of this study was to evaluate the cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin as initial therapy for patients with Chronic Hepatitis C (CHC). Methods: We used a pre-existent Markov model of disease progression in which two cohorts of patients received peginterferon α-2a plus ribavirin or peginterferon α-2b plus ribavirin for 48 weeks and were followed for their expected lifetimes. The reference patient was a 45-year-old male with CHC without cirrhosis. The sustained virological responses (SVR) with peginterferon α-2a plus ribavirin and peginterferon α-2b plus ribavirin, were taken from two different publications. Utilities and costs for each health state were based on literature estimates and on Italian treatment patterns. Costs in 2005 euros and benefits were discounted at 3{\%}. Sensitivity analyses on key clinical and economic parameters were performed. The analysis was conducted from the perspective of the Italian National Health Service. Results: For the two cohorts expected life-years with peginterferon α-2a plus ribavirin versus peginterferon α-2a plus ribavirin were respectively 30.85 and 30.15 years. Quality-adjusted life years for peginterferon α-2a plus ribavirina were 17.69, and for peginterferon α-2b plus ribavirin were 17.08. The expected cost was €18,272 with peginterferon α-2a plus ribavirin and €18,549 with peginterferon α-2b plus ribavirin. Conclusion: This economic evaluation suggests that peginterferon α-2a plus ribavirin is a dominant strategy versus peginterferon α-2b plus ribavirin for treatment of adults with CHC, under some assumptions regarding treatment effectiveness and model structure.",
author = "Roberto Ravasio and P. Sacchi and L. Maiocchi and S. Patruno and R. Bruno and G. Filice",
year = "2005",
language = "Italian",
volume = "7",
pages = "207--218",
journal = "PharmacoEconomics - Italian Research Articles",
issn = "1590-9158",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Costo efficacia di peginterferone α-2a + ribavirina verso peginterferone α-2b + ribavirina nel trattamento dell'epatite cronica di tipo C in pazienti non pretrattati

AU - Ravasio, Roberto

AU - Sacchi, P.

AU - Maiocchi, L.

AU - Patruno, S.

AU - Bruno, R.

AU - Filice, G.

PY - 2005

Y1 - 2005

N2 - Introduction: The objective of this study was to evaluate the cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin as initial therapy for patients with Chronic Hepatitis C (CHC). Methods: We used a pre-existent Markov model of disease progression in which two cohorts of patients received peginterferon α-2a plus ribavirin or peginterferon α-2b plus ribavirin for 48 weeks and were followed for their expected lifetimes. The reference patient was a 45-year-old male with CHC without cirrhosis. The sustained virological responses (SVR) with peginterferon α-2a plus ribavirin and peginterferon α-2b plus ribavirin, were taken from two different publications. Utilities and costs for each health state were based on literature estimates and on Italian treatment patterns. Costs in 2005 euros and benefits were discounted at 3%. Sensitivity analyses on key clinical and economic parameters were performed. The analysis was conducted from the perspective of the Italian National Health Service. Results: For the two cohorts expected life-years with peginterferon α-2a plus ribavirin versus peginterferon α-2a plus ribavirin were respectively 30.85 and 30.15 years. Quality-adjusted life years for peginterferon α-2a plus ribavirina were 17.69, and for peginterferon α-2b plus ribavirin were 17.08. The expected cost was €18,272 with peginterferon α-2a plus ribavirin and €18,549 with peginterferon α-2b plus ribavirin. Conclusion: This economic evaluation suggests that peginterferon α-2a plus ribavirin is a dominant strategy versus peginterferon α-2b plus ribavirin for treatment of adults with CHC, under some assumptions regarding treatment effectiveness and model structure.

AB - Introduction: The objective of this study was to evaluate the cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin as initial therapy for patients with Chronic Hepatitis C (CHC). Methods: We used a pre-existent Markov model of disease progression in which two cohorts of patients received peginterferon α-2a plus ribavirin or peginterferon α-2b plus ribavirin for 48 weeks and were followed for their expected lifetimes. The reference patient was a 45-year-old male with CHC without cirrhosis. The sustained virological responses (SVR) with peginterferon α-2a plus ribavirin and peginterferon α-2b plus ribavirin, were taken from two different publications. Utilities and costs for each health state were based on literature estimates and on Italian treatment patterns. Costs in 2005 euros and benefits were discounted at 3%. Sensitivity analyses on key clinical and economic parameters were performed. The analysis was conducted from the perspective of the Italian National Health Service. Results: For the two cohorts expected life-years with peginterferon α-2a plus ribavirin versus peginterferon α-2a plus ribavirin were respectively 30.85 and 30.15 years. Quality-adjusted life years for peginterferon α-2a plus ribavirina were 17.69, and for peginterferon α-2b plus ribavirin were 17.08. The expected cost was €18,272 with peginterferon α-2a plus ribavirin and €18,549 with peginterferon α-2b plus ribavirin. Conclusion: This economic evaluation suggests that peginterferon α-2a plus ribavirin is a dominant strategy versus peginterferon α-2b plus ribavirin for treatment of adults with CHC, under some assumptions regarding treatment effectiveness and model structure.

UR - http://www.scopus.com/inward/record.url?scp=32344434249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32344434249&partnerID=8YFLogxK

M3 - Articolo

VL - 7

SP - 207

EP - 218

JO - PharmacoEconomics - Italian Research Articles

JF - PharmacoEconomics - Italian Research Articles

SN - 1590-9158

IS - 3

ER -